secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2023-03-09T23:59:59+00:00
Accession:  0001628280-23-007294
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE reports FY2022 net loss $23.2M; VYN201 Phase 1b in vitiligo dosing
-----------------------------------------------------------------------

- GAAP net loss of $23.2M for FY2022 vs $73.3M in 2021; adjusted net loss $18.9M.
- Topline Phase 1b data for VYN201 (pan-BD BET inhibitor) in vitiligo expected mid-2023.
- Positive preliminary Phase 1a safety data for VYN201; three doses selected for Phase 1b.
- Regained Nasdaq minimum bid price compliance after 1-for-18 reverse stock split in Feb 2023.
- VYN202 option agreement extended to April 2023; IND-enabling studies planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000162828023007294/0001628280-23-007294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000162828023007294/mnlo-20230309.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-007294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer